Evelo Biosciences is discovering and developing oral biologics that act on cells in the small intestine with systemic therapeutic effects. Co.'s primary product candidates are orally delivered pharmaceutical preparations of naturally occurring, specific single strains of microbes. Co.'s product candidate, EDP1815, is being developed for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Additional product candidates include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
EVLO — Key Stats (updated Friday, December 3, 10:25 AM)